Uterotonics in Postpartum Hemorrhage
common.study.values.description
“Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial”
The aim of this study is to evaluate in a randomized fashion the comparative efficacy of two second-line medications, methylergonovine and carboprost for treating atonic postpartum hemorrhage (PPH). The investigators hypothesize that administration of methylergonovine will produce superior uterine tone to carboprost in atonic PPH.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
 common.study.methods.has-drugs-yes
                                    common.study.methods.has-drugs-yes
                                 common.study.methods.is-healthy-no
                                        common.study.methods.is-healthy-no
                                Drug - 15-methyl prostaglandin F2α
Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the "carboprost" study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine.
Drug - Methylergonovine Maleate
Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the "methergine" study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost.
participant.views.study.view.additional
participant.views.study.view.scientific-title
Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial
common.study.values.clinical-trial-id
NCT03584854
participant.views.study.view.id
e9rrDa
 
    
    